Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
Industry, Sector and Symbol:
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Symbol: NASDAQ:LPCN
- CUSIP: N/A
- Web: www.lipocine.com
- Market Cap: $70.11 million
- Outstanding Shares: 19,261,000
- 50 Day Moving Avg: $3.83
- 200 Day Moving Avg: $3.77
- 52 Week Range: $2.51 - $9.59
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.99
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.29 per share
- Price / Book: 2.82
- EBIDTA: ($16,260,000.00)
- Return on Equity: -59.35%
- Return on Assets: -55.10%
- Current Ratio: 18.73%
- Quick Ratio: 18.73%
- Average Volume: 160,758 shs.
- Beta: 1.88
- Short Ratio: 9.48
Frequently Asked Questions for Lipocine (NASDAQ:LPCN)
What is Lipocine's stock symbol?
Lipocine trades on the NASDAQ under the ticker symbol "LPCN."
How were Lipocine's earnings last quarter?
Lipocine Inc (NASDAQ:LPCN) announced its quarterly earnings data on Monday, May, 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. View Lipocine's Earnings History.
Where is Lipocine's stock going? Where will Lipocine's stock price be in 2017?
3 analysts have issued 12-month price targets for Lipocine's stock. Their forecasts range from $10.00 to $30.00. On average, they anticipate Lipocine's share price to reach $21.67 in the next twelve months. View Analyst Ratings for Lipocine.
Are investors shorting Lipocine?
Lipocine saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 1,774,743 shares, an increase of 6.2% from the March 31st total of 1,671,769 shares. Based on an average daily volume of 94,462 shares, the short-interest ratio is currently 18.8 days.
Who are some of Lipocine's key competitors?
Some companies that are related to Lipocine include Agile Therapeutics (AGRX), pSivida Corp. (PSDV), Galectin Therapeutics (GALT), Sophiris Bio (SPHS), Kalvista Pharmaceuticals (KALV), Innocoll Holdings PLC (INNL), Juniper Pharmaceuticals (JNP), SCYNEXIS (SCYX), Evoke Pharma (EVOK), Fibrocell Science (FCSC), Sonoma Pharmaceuticals (SNOA), Celator Pharmaceuticals (CPXX), NephroGenex (NRX), Parnell Pharmaceuticals Holdings Ltd (PARN) and Sagent Pharmaceuticals (SGNT).
Who are Lipocine's key executives?
Lipocine's management team includes the folowing people:
- Mahesh V. Patel Ph.D., Chairman of the Board, President, Chief Executive Officer
- Morgan R. Brown CPA, Chief Financial Officer, Executive Vice President
- Gregory Bass, Executive Vice President, Chief Commercial Officer
- Stephen Anthony Hill M.D., Lead Independent Director
- Jeffrey A. Fink, Director
- Richard Dana Ono, Director
- John W. Higuchi, Non-Executive Director
Who owns Lipocine stock?
Lipocine's stock is owned by a number of of institutional and retail investors. Top institutional investors include Royce & Associates LP (6.34%), VHCP Management II LLC (2.26%), Vanguard Group Inc. (2.10%), Dimensional Fund Advisors LP (1.39%), JPMorgan Chase & Co. (1.04%) and Ameriprise Financial Inc. (0.71%). Company insiders that own Lipocine stock include John W Higuchi and Mahesh V Patel. View Institutional Ownership Trends for Lipocine.
Who sold Lipocine stock? Who is selling Lipocine stock?
Lipocine's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., TIAA CREF Investment Management LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Lipocine.
Who bought Lipocine stock? Who is buying Lipocine stock?
Lipocine's stock was acquired by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Vanguard Group Inc., Parametric Portfolio Associates LLC, KCG Holdings Inc., Geode Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Lipocine stock in the last two years include John W Higuchi and Mahesh V Patel. View Insider Buying and Selling for Lipocine.
How do I buy Lipocine stock?
Shares of Lipocine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lipocine's stock price today?
MarketBeat Community Rating for Lipocine (NASDAQ LPCN)MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Lipocine stock can currently be purchased for approximately $3.64.
Earnings History for Lipocine (NASDAQ:LPCN)Earnings History by Quarter for Lipocine (NASDAQ LPCN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Lipocine (NASDAQ:LPCN)
2017 EPS Consensus Estimate: ($0.95)
2018 EPS Consensus Estimate: ($0.24)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Lipocine (NASDAQ:LPCN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Lipocine (NASDAQ:LPCN)
Insider Ownership Percentage: 10.00%Insider Trades by Quarter for Lipocine (NASDAQ:LPCN)
Institutional Ownership Percentage: 45.02%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/30/2015||John W Higuchi||Director||Buy||5,000||$12.68||$63,400.00|| |
|9/30/2015||Mahesh V. Patel||CEO||Buy||4,000||$11.84||$47,360.00|| |
|11/25/2014||Mahesh V Patel||CEO||Buy||2,000||$5.10||$10,200.00|| |
|11/24/2014||Mahesh V Patel||CEO||Buy||2,000||$5.45||$10,900.00|| |
|11/19/2014||Richard Dana Ono||Director||Buy||4,000||$5.14||$20,560.00|| |
|11/14/2014||Mahesh V Patel||CEO||Buy||2,000||$5.06||$10,120.00|| |
|11/13/2014||Mahesh V Patel||CEO||Buy||2,000||$5.05||$10,100.00|| |
|11/13/2014||Stephen A Hill||Director||Buy||4,000||$4.95||$19,800.00|| |
Headline Trends for Lipocine (NASDAQ:LPCN)
Latest Headlines for Lipocine (NASDAQ:LPCN)
Lipocine (LPCN) Chart for Monday, May, 29, 2017